Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 9/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355037 | 0.89 | CDK5 (0.41) | CDK5CDK5R1SMYD3DYRK1AROCK1 | |
| SCHEMBL5342113 | 0.86 | CDK5 (0.46) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL5338130 | 0.84 | CDK5 (0.45) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL5342649 | 0.82 | CDK5 (0.52) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL6867013 | 0.81 | CDK5 (0.47) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL5342249 | 0.81 | CDK5 (0.43) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL5342095 | 0.81 | CDK5 (0.43) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL5345465 | 0.80 | CDK5 (0.49) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL5345480 | 0.80 | CDK5 (0.45) | CDK5CDK5R1DYRK1AROCK1POLQ | |
| SCHEMBL5354577 | 0.80 | CDK5 (0.53) | CDK5CDK5R1DYRK1AROCK1POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | CDK5 64/4885CDK5R1 359/4885SMYD3 1300/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | CDK5 64/4885CDK5R1 359/4885SMYD3 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.